The FDA Approves Novocure's New Head Flexible Electrode Transducer Arrays For Use With Optune Gio For Adult Patients With Glioblastoma Multiforme, Novocure Plans To Convert Optune Gio Users In The U.S. To The New HFE Arrays Through The First Half Of...
The FDA Approves Novocure's New Head Flexible Electrode Transducer Arrays For Use With Optune Gio For Adult Patients With Glioblastoma Multiforme, Novocure Plans To Convert Optune Gio Users In The U.S. To The New HFE Arrays Through The First Half Of...
美國食品藥品監督管理局批准novocure的新型頭部柔性電極換能器陣列用於與Optune Gio結合治療患有多形性膠質母細胞瘤的成年人，novocure計劃在今年上半年將美國的Optune Gio用戶轉換爲新的HFE陣列。
The FDA Approves Novocure's New Head Flexible Electrode Transducer Arrays For Use With Optune Gio For Adult Patients With Glioblastoma Multiforme, Novocure Plans To Convert Optune Gio Users In The U.S. To The New HFE Arrays Through The First Half Of 2025 Through A Controlled Transition Plan
美國食品藥品管理局批准Novocure的新型頭部柔性電極探頭陣列與Optune Gio一起用於成年多形膠質母細胞瘤患者，Novocure計劃通過受控過渡計劃，在2025年上半年之前將美國的Optune Gio用戶轉換爲新的HFE陣列
Optune Gio is a wearable, portable device that produces alternating electric fields known as Tumor Treating Fields (TTFields), which are delivered through non-invasive, wearable arrays. TTFields exert physical forces on the electrically charged components of dividing cancer cells, which disrupt the rapid cell division exhibited by cancer cells.
Optune Gio是一種可穿戴的便攜式設備，可產生稱爲腫瘤治療場（TTFields）的交替電場，通過非侵入性的可穿戴陣列傳輸。TTFields 對分裂癌細胞的帶電成分施加物理力，從而破壞癌細胞表現出的快速細胞分裂。
The new HFE arrays utilize a flexible polymer material in place of the ceramic discs used in the current Optune Gio arrays, making them one-third lighter and 50% thinner.
新的HFE陣列使用柔性聚合物材料代替了當前Optune Gio陣列中使用的陶瓷圓盤，使其重量減輕了三分之一，薄了50％。
資訊熱榜
更新時間